190 related articles for article (PubMed ID: 18719071)
1. Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant.
Howell JE; Szabatura AH; Hatfield Seung A; Nesbit SA
J Oncol Pharm Pract; 2008 Sep; 14(3):157-62. PubMed ID: 18719071
[TBL] [Abstract][Full Text] [Related]
2. [Ifosfamide induced encephalopathy: 15 observations].
Dufour C; Grill J; Sabouraud P; Behar C; Munzer M; Motte J; Oberlin O; Paci A; Hartmann O
Arch Pediatr; 2006 Feb; 13(2):140-5. PubMed ID: 16364615
[TBL] [Abstract][Full Text] [Related]
3. Possible contribution of aprepitant to ifosfamide-induced neurotoxicity.
Jarkowski A
Am J Health Syst Pharm; 2008 Dec; 65(23):2229-31. PubMed ID: 19020190
[TBL] [Abstract][Full Text] [Related]
4. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
[TBL] [Abstract][Full Text] [Related]
5. Aprepitant-associated ifosfamide neurotoxicity.
Hansen Ho ; Yuen C
J Oncol Pharm Pract; 2010 Jun; 16(2):137-8. PubMed ID: 19759053
[No Abstract] [Full Text] [Related]
6. Urinary proton magnetic resonance studies of early ifosfamide-induced nephrotoxicity and encephalopathy.
Foxall PJ; Singer JM; Hartley JM; Neild GH; Lapsley M; Nicholson JK; Souhami RL
Clin Cancer Res; 1997 Sep; 3(9):1507-18. PubMed ID: 9815837
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment of ifosfamide neurotoxicity with dexmedetomidine.
Bernard PA; McCabe T; Bayliff S; Hayes D
J Oncol Pharm Pract; 2010 Dec; 16(4):262-5. PubMed ID: 20118215
[TBL] [Abstract][Full Text] [Related]
8. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
[TBL] [Abstract][Full Text] [Related]
9. Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism.
de Jonge ME; Huitema AD; Holtkamp MJ; van Dam SM; Beijnen JH; Rodenhuis S
Cancer Chemother Pharmacol; 2005 Oct; 56(4):370-8. PubMed ID: 15838656
[TBL] [Abstract][Full Text] [Related]
10. [Treatment and prevention of iphosphamide-induced encephalopathy].
Sunela K; Bärlund M
Duodecim; 2016; 132(4):314-7. PubMed ID: 27017785
[TBL] [Abstract][Full Text] [Related]
11. Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients.
Nygren P; Hande K; Petty KJ; Fedgchin M; van Dyck K; Majumdar A; Panebianco D; de Smet M; Ahmed T; Murphy MG; Gottesdiener KM; Cocquyt V; van Belle S
Cancer Chemother Pharmacol; 2005 Jun; 55(6):609-16. PubMed ID: 15723220
[TBL] [Abstract][Full Text] [Related]
12. An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center.
Szabatura AH; Cirrone F; Harris C; McDonnell AM; Feng Y; Voit D; Neuberg D; Butrynski J; Fisher DC
J Oncol Pharm Pract; 2015 Jun; 21(3):188-93. PubMed ID: 24664476
[TBL] [Abstract][Full Text] [Related]
13. Ifosfamide-induced encephalopathy in patients with uterine sarcoma.
Liu YL; Tsai SH; Chang FW; Yu MH
Taiwan J Obstet Gynecol; 2010 Mar; 49(1):77-80. PubMed ID: 20466298
[TBL] [Abstract][Full Text] [Related]
14. Antiemetic neurokinin-1 antagonist aprepitant and ifosfamide-induced encephalopathy.
Durand JP; Gourmel B; Mir O; Goldwasser F
Ann Oncol; 2007 Apr; 18(4):808-9. PubMed ID: 17389531
[No Abstract] [Full Text] [Related]
15. Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials.
Gralla RJ; de Wit R; Herrstedt J; Carides AD; Ianus J; Guoguang-Ma J; Evans JK; Horgan KJ
Cancer; 2005 Aug; 104(4):864-8. PubMed ID: 15973669
[TBL] [Abstract][Full Text] [Related]
16. Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Rev Anticancer Ther; 2004 Oct; 4(5):715-24. PubMed ID: 15485308
[TBL] [Abstract][Full Text] [Related]
17. Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients.
Loos WJ; de Wit R; Freedman SJ; Van Dyck K; Gambale JJ; Li S; Murphy GM; van Noort C; de Bruijn P; Verweij J
Cancer Chemother Pharmacol; 2007 Feb; 59(3):407-12. PubMed ID: 17051369
[TBL] [Abstract][Full Text] [Related]
18. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
[TBL] [Abstract][Full Text] [Related]
19. Aprepitant, fosaprepitant and risk of ifosfamide-induced neurotoxicity: a systematic review.
Vazirian F; Samadi S; Rahimi H; Sadeghi M; Mohammadpour AH
Cancer Chemother Pharmacol; 2022 Jul; 90(1):1-6. PubMed ID: 35635561
[TBL] [Abstract][Full Text] [Related]
20. Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor.
Raney B; Ensign LG; Foreman J; Khan F; Newton W; Ortega J; Ragab A; Wharam M; Wiener E; Maurer H
Am J Pediatr Hematol Oncol; 1994 Nov; 16(4):286-95. PubMed ID: 7978043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
